XML 174 R111.htm IDEA: XBRL DOCUMENT
v3.25.1

Share-based payments - Disclosure of Number and Weighted Average Remaining Contractual Life of Founders' Warrants, Warrants, and Free Shares Outstanding (Details) |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 27, 2023 shares | Jun. 22, 2022 shares | Apr. 21, 2021 € / shares | Apr. 20, 2021 shares € / shares | Mar. 17, 2020 shares € / shares | Mar. 29, 2019 shares € / shares | Jul. 27, 2018 shares € / shares | Jan. 07, 2017 shares € / shares | Feb. 02, 2016 shares € / shares | Jun. 25, 2015 shares € / shares | Jun. 10, 2015 shares € / shares | Feb. 10, 2015 shares € / shares | Sep. 16, 2014 shares € / shares | Dec. 31, 2024 shares | Dec. 31, 2024 shares € / shares | Dec. 31, 2024 shares uSDollarPerEuro | Dec. 31, 2023 shares | Dec. 31, 2024 uSDollarPerEuro | Dec. 31, 2022 shares
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,936,540 | 4,936,540 | 4,936,540 | 4,172,089 |  | 3,513,246
BSPCE |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 467,067 | 467,067 | 467,067 | 557,367 |  | 614,726
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
BSPCE 09-2014 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  |  | 97,200 | 0 |  |  | 0 |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  |  | € 18.68 |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 85,750 |  | 86,150
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 97,200 | 97,200 | 97,200 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 85,750 |  |  |  |  |
BSPCE 2015-1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  | 71,650 |  | 0 |  |  | 0 |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  | € 18.57 |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 67,750 | 67,750 | 67,750 | 68,100 |  | 68,450
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,900 | 3,900 | 3,900 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 350 |  |  |  |  |
BSPCE 2015-3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  | 53,050 |  |  | 0 |  |  | 0 |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  |  |  | € 20.28 |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 27,350 | 27,350 | 27,350 | 28,400 |  | 30,350
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,700 | 25,700 | 25,700 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,050 |  |  |  |  |
BSPCE 2016 Ordinary |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  | 126,400 |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  | € 14.46 |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 96,817 | 96,817 | 96,817 |  |  |
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 333 | 333 | 333 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 29,250 | 29,250 | 29,250 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,050 |  |  |  |  |
BSPCE 2016 Performance |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  | 129,250 |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  | € 14.46 |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 98,100 | 98,100 | 98,100 |  |  |
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 31,150 | 31,150 | 31,150 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,050 |  |  |  |  |
BSPCE 2017 Ordinary |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  | 117,650 |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  | € 15.93 |  |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 97,050 | 97,050 | 97,050 |  |  |
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,600 | 20,600 | 20,600 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,050 |  |  |  |  |
BSPCE 2017 Performance |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  | 80,000 |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  | € 15.93 |  |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 80,000 | 80,000 | 80,000 |  |  |
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
BSA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 141,251 | 141,251 | 141,251 | 151,251 |  | 185,251
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
BSA 2014 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  |  | 14,000 | 0 |  |  | 0 |  |
Grant price (in euro per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  |  | € 4.87 |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  |  | € 17.67 |  | € 17.67 |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 10,000 |  | 10,000
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,000 | 14,000 | 14,000 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,000 |  |  |  |  |
BSA 2015-1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  | 26,000 |  | 0 |  |  | 0 |  |
Grant price (in euro per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  | € 4.87 |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  |  |  |  | € 17.67 |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 21,000 | 21,000 | 21,000 | 21,000 |  | 21,000
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,000 | 5,000 | 5,000 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
BSA 2015-2 a |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  | 64,000 |  |  |  | 0 |  |  | 0 |  |
Grant price (in euro per share) | € / shares |  |  |  |  |  |  |  |  |  | € 5.00 |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  |  |  |  | € 19.54 |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 64,000 | 64,000 | 64,000 | 64,000 |  | 64,000
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
BSA 2018-2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  | 5,820 |  |  |  |  |  |  | 0 |  |  | 0 |  |
Grant price (in euro per share) | € / shares |  |  |  |  |  |  | € 2.36 |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  |  | € 16.10 |  |  |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 5,820 | 5,820 | 5,820 | 5,820 |  | 5,820
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
BSA 2019-1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  | 18,000 |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Grant price (in euro per share) | € / shares |  |  |  |  |  | € 1.15 |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  |  | € 11.66 |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,000 | 18,000 | 18,000 | 18,000 |  | 18,000
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
BSA 2020 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  | 18,000 |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Grant price (in euro per share) | € / shares |  |  |  |  | € 0.29 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  |  |  | € 6.59 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,000 | 18,000 | 18,000 | 18,000 |  | 18,000
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
BSA 2021 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  | 48,103 |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Grant price (in euro per share) | € / shares |  |  |  | € 2.95 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price (in euros per share) | € / shares |  |  | € 13.47 | € 13.47 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 14,431 | 14,431 | 14,431 | 14,431 |  | 14,431
Number of awards, exercised (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 33,672 | 33,672 | 33,672 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
AGA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 866,320 |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 815,920 | 815,920 | 815,920 | 1,127,296 |  | 653,746
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 293,523 |  |  | 354,510 |  |
AGA 2022 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) |  | 300,039 |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 | 293,776 | 0 | 299,035
Number of awards, exercised (in shares) | uSDollarPerEuro |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 293,523 |
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 293,523 |  | 293,523 | 0 |  |
Number of awards lapsed or cancelled (in shares) | uSDollarPerEuro |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,516 |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 253 |  |  |  |  |
AGA 2023 - P1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) | 427,110 |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 427,110 |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 392,460 | 392,460 | 392,460 | 400,960 |  | 0
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 34,650 | 34,650 | 34,650 |  |  |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,500 |  |  |  |  |
AGA 2023 - P2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of number and weighted average remaining contractual life of other equity instruments outstanding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of awards issued (in shares) | 439,210 |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 439,210 |  |
Number of awards outstanding (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 423,460 | 423,460 | 423,460 | 432,560 | 423,460 | 0
Awards exercised during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  | 0 |  |
Number of awards lapsed or cancelled (in shares) | uSDollarPerEuro |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,750 |
Number of awards lapsed or cancelled during the period (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,100 |  |  |  |  |

X
- Definition The exercise price of share options granted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 47 -Subparagraph a -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ExercisePriceShareOptionsGranted2019
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 47 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IFRS -Number 2 -IssueDate 2024-01-01 -Paragraph 45 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure Of Number And Weighted Average Remaining Contractual Life Of Other Equity Instruments Outstanding + References No definition available. + Details
Name: | nbx_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOtherEquityInstrumentsOutstandingLineItems
Namespace Prefix: | nbx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number Of Awards Exercised In Share-based Payment Arrangement + References No definition available. + Details
Name: | nbx_NumberOfAwardsExercisedInShareBasedPaymentArrangement
Namespace Prefix: | nbx_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Awards Forfeited In Share-based Payment Arrangement + References No definition available. + Details
Name: | nbx_NumberOfAwardsForfeitedInShareBasedPaymentArrangement
Namespace Prefix: | nbx_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Other Equity Instruments Forfeited in Share-based Payment Arrangement Including Shares Lapsed or Cancelled During the Period + References No definition available. + Details
Name: | nbx_NumberOfOtherEquityInstrumentsForfeitedInShareBasedPaymentArrangementIncludingSharesLapsedOrCancelledDuringThePeriod
Namespace Prefix: | nbx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE092014Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20151Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE20153Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2016PerformanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017OrdinaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSPCE2017PerformanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2014Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20151Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20152Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20182Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA20191Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2020Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_BSA2021AMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2022Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=nbx_AGA2023P2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |